3 results
The primary objective of this study is to assess the overall safety and tolerability of subcutaneous (SC) trastuzumab using SID (Singel Injection Device) in HER2-positive eBC (early Breast Cancer) patients self-administered at home under supervision…
1. To assess the safety, tolerability, and efficacy of ABBV-3373 administered every other week (eow) intravenously (IV) in subjects with moderately to severely active RA on background MTX.2. To compare clinical efficacy of ABBV-3373 with adalimumab…
This clinical performance study will evaluate the effectiveness of the Ki 67 IHC MIB-1 pharmDx (Dako Omnis) to identify estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- early breast cancer patients whose tumours score Ki-67…